Vector Expands Patent Portfolio for Precision Drug Delivery
MEQUON, Wis., July 15, 2026 Vector Science & Therapeutics has significantly expanded its intellectual property (IP) portfolio with 15...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
MEQUON, Wis., July 15, 2026 Vector Science & Therapeutics has significantly expanded its intellectual property (IP) portfolio with 15...
MEQUON, Wis., July 7, 2026 Vector Science & Therapeutics Corp. has entered into a landmark exclusive licensing and cGMP...
SEATTLE, June 30, 2026 AGC Biologics has announced a strategic partnership with Pyramid Pharma Services to expand its U.S.-based...
